VIP (Vasoactive Intestinal Peptide) vs Adrenomedullin

VIP and Adrenomedullin represent two vasoactive peptides with distinct but overlapping research profiles. VIP, a neuropeptide consisting of 28 amino acids (MW ~3326.8 g/mol), is found throughout the nervous system, lungs, and gastrointestinal tract, where it is investigated for its vasodilatory, bronchodilatory, and immunomodulatory effects. In contrast, Adrenomedullin is a 52-amino-acid peptide (MW ~6028 g/mol) primarily expressed in cardiovascular tissues, lungs, and kidneys. This peptide is chiefly examined as a prognostic biomarker (MR-proADM) for conditions such as sepsis and heart failure. The following sections will explore their mechanisms of action, the strength of supporting evidence, dosing protocols reported in studies, and safety considerations, providing clarity on their respective roles in research.

VIP operates through the VPAC1 and VPAC2 receptors, facilitating a range of physiological responses, including vasodilation and bronchodilation, as well as immune modulation. Its expression in both central and peripheral nervous systems, along with the lungs and gastrointestinal tract, underscores its diverse biological functions. Clinical investigations, particularly involving synthetic aviptadil (RLF-100), have highlighted its potential in treating ARDS associated with COVID-19, showcasing lung-protective properties. Moreover, preclinical studies have suggested neuroprotective effects in models of neurodegeneration, although human data outside of ARDS remain sparse. VIP's diagnostic utility extends to identifying VIPomas, reinforcing its relevance in clinical contexts. While research supports its anti-inflammatory and pulmonary protective capabilities, further exploration in human trials is necessary to fully elucidate its therapeutic potential.

Adrenomedullin is characterized by its 52-amino-acid structure (MW ~6028 g/mol) and was first isolated from human pheochromocytoma tissues. This peptide is widely distributed in cardiovascular tissues, lungs, kidneys, and adrenal glands, where it exerts potent vasodilatory, natriuretic, and cardioprotective effects. Currently, Adrenomedullin is under investigation primarily as a prognostic biomarker (MR-proADM) for sepsis and heart failure, with studies suggesting its ability to predict mortality independently of traditional markers. Although it demonstrates significant vasodilatory effects in clinical settings, no therapeutic formulation of the peptide has received regulatory approval. The mechanistic pathway involves interaction with the calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), highlighting its role in cardiovascular homeostasis. While promising, the lack of approved therapeutic uses necessitates further research to establish its clinical applications.

VIP and Adrenomedullin serve distinct roles in research, with minimal overlap in their applications. VIP is predominantly explored within pulmonary research, particularly in contexts like ARDS and pulmonary hypertension, as well as in immunomodulation and neuroprotection. Its therapeutic potential is often the focus of studies aimed at intervention strategies. Conversely, Adrenomedullin is primarily investigated as a biomarker for sepsis and heart failure, with a significant emphasis on its prognostic value through the MR-proADM fragment. While both peptides share vasodilatory properties, their research trajectories diverge, with VIP oriented towards therapeutic interventions and Adrenomedullin primarily serving as a diagnostic tool. This distinction is crucial for researchers when selecting the appropriate peptide for their specific investigations.

VIP is characterized by a very short plasma half-life of approximately 1-2 minutes, which limits its systemic effects and necessitates continuous infusion in experimental settings. The primary adverse effect associated with VIP is hypotension, attributable to its potent vasodilatory properties. Higher doses may also lead to gastrointestinal symptoms such as diarrhea and flushing, which are consistent with its physiological roles. In contrast, Adrenomedullin lacks extensive human safety data stemming from controlled therapeutic trials. Experimental intravenous infusion in healthy volunteers has been associated with hypotension and reflex tachycardia, raising concerns about potential hemodynamic instability. Both peptides present risks of excessive vasodilation, necessitating careful monitoring in research environments to mitigate adverse effects.